Molecular basis of bortezomib resistance: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein
- 15 September 2008
- journal article
- Published by American Society of Hematology in Blood
- Vol. 112 (6), 2489-2499
- https://doi.org/10.1182/blood-2007-08-104950
Abstract
The proteasome inhibitor bortezomib is a novel anticancer drug that has shown promise in the treatment of refractory multiple myeloma. However, its clinical efficacy has been hampered by the emergence of drug-resistance phenomena, the molecular basis of which remains elusive. Toward this end, we here developed high levels (45- to 129-fold) of acquired resistance to bortezomib in human myelomonocytic THP1 cells by exposure to stepwise increasing (2.5-200 nM) concentrations of bortezomib. Study of the molecular mechanism of bortezomib resistance in these cells revealed (1) an Ala49Thr mutation residing in a highly conserved bortezomib-binding pocket in the proteasome β5-subunit (PSMB5) protein, (2) a dramatic overexpression (up to 60-fold) of PSMB5 protein but not of other proteasome subunits including PSMB6, PSMB7, and PSMA7, (3) high levels of cross-resistance to β5 subunit-targeted cytotoxic peptides 4A6, MG132, MG262, and ALLN, but not to a broad spectrum of chemotherapeutic drugs, (4) no marked changes in chymotrypsin-like proteasome activity, and (5) restoration of bortezomib sensitivity in bortezomib-resistant cells by siRNA-mediated silencing of PSMB5 gene expression. Collectively, these findings establish a novel mechanism of bortezomib resistance associated with the selective overexpression of a mutant PSMB5 protein.Keywords
This publication has 52 references indexed in Scilit:
- Proteasome Inhibitors in Cancer Therapy: Lessons from the First DecadeClinical Cancer Research, 2008
- Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelomaBlood, 2007
- Profiling Proteasome Activity in Tissue with Fluorescent ProbesMolecular Pharmaceutics, 2007
- Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cellsJournal of Cellular Biochemistry, 2007
- Molecular basis of antifolate resistanceCancer and Metastasis Reviews, 2007
- Proteasome inhibitors: antitumor effects and beyondLeukemia, 2006
- Drug discovery in the ubiquitin–proteasome systemNature Reviews Drug Discovery, 2006
- Oxidative Deboronation of the Peptide Boronic Acid Proteasome Inhibitor Bortezomib: Contributions from Reactive Oxygen Species in This Novel Cytochrome P450 ReactionChemical Research in Toxicology, 2006
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006
- The compressed feature matrix?a fast method for feature based substructure searchJournal of Molecular Modeling, 2003